Biotech Values

[DewDiligence]

Re: FRX, CYPB

In fibromyalgia and its ancillary indications, I think companies need two solid pivotal trials to have a good chance for approval. If FRX and CYPB try to pull a “Dendreon” and go to the FDA with one good trial and one that’s merely “supportive,” I think they’ll likely end up with an approvable letter.

>It is not clear from the PR that FRX is continuing the same payment scheme (where FRX pays the vast bulk of the trial costs).<

If the funding arrangement has changed to a material degree, CYPB will have to issue a Form-8K within the next day or so. Regards, Dew